Is Gleason 6 a cancer?

Active Surveillance, Diagnosis / By / / 2 minutes of reading

On July 29, 2021, Drs. Ming Zhou, Pathologist-in-Chief and Chair of Anatomic and Clinical Pathology, Tufts Medical School, and Dr. Scott Eggener, Vice Chair of Urology at the University of Chicago, debated this question: Is Gleason 6 a cancer? The doctors presented their cases at the AnCan program in this video individually. One of Eggener’s key points is that he has never seen a patient die from Gleason 6 so why call it a cancer. Zhou took the stand that if it looks like a cancer, which Gleason does under the microscope, then it’s a cancer. The question-and-answer period covered such …

Is Gleason 6 a cancer? Read More »

What is Right for Me in My Prostate Cancer Treatment?

Active Surveillance, Imaging / By / / 1 minute of reading

Video is now available of the fourth webinar in Us TOO‘s series, What is Right for Me in My Prostate Cancer Treatment?, a discussion on Imaging. Continuing advances in imaging technology and usage can mean more accurate testing and diagnosis related to prostate cancer, and can help guide patients toward the best treatment options for them. Hear the latest from the experts on this very important topic. This webinar was recorded on June 24th. View the Video here. Featuring: Brian T. Helfand MD, PhD – Chief, Division of Urology, Ronald L. Chez Family and Richard Melman Family Endowed Chair of …

What is Right for Me in My Prostate Cancer Treatment? Read More »

Prostate Cancer – Active Surveillance and More…Past, present and Future

Videos, Active Surveillance / By / / 1 minute of reading

This seminar  with Dr Klotz, regarded as one of the pioneers of AS, and a fellow Canadian, will be of special interest to anyone on or interested in AS. This free webinar is available here.  You will be asked to register and give your email address.  Once you check the box at the bottom and click the Register button, you will taken to the presentation.

Video: Dr. Eric Klein discusses Active Surveillance

Videos, Active Surveillance / By / / 1 minute of reading

Renowned Cleveland Clinic Urologist Dr. Eric Klein discusses Active Surveillance. Dr. Klein answers the questions: “What do I actually do while I’m on Active Surveillance?” What tests should I be taking and how often? How do I know if I qualify for Active Surveillance? What indicators will tell me that I must go off Active Surveillance and seek active treatment? Dr. Klein indicated that 15% of Gleason 6s have a molecular make up which may indicate the presence of a more aggressive cancer and in his opinion, genomic testing is critical to identify those cancers. Click here to view.

Video: “Active Surveillance Decisions”

Videos, Awareness Nights, Active Surveillance / By / / 1 minute of reading

November 2019 Awareness Night Active Surveillance Decisions (Why, Who, How, and When you know it’s time to be treated) Dr. Danny Vesprini, MD, MSc, FRCPC Affiliate Scientist, Biological Sciences, Odette Cancer Research Program, Sunnybrook Research Institute Radiation Oncologist, Dept. of Radiation Oncology, Sunnybrook Odette Cancer Centre Asst. Prof., Dept. of Radiation Oncology, U. of Toronto     CLICK ON THE ARROW TO START THE VIDEO The Complete Presentation 1:04:57 minutes <

Gleason 6 Is Bogus Prostate Cancer

PSA Screening, Active Surveillance / By / / 1 minute of reading

Noted urologic surgeon Bert Vorstman, MD, MS, FAAP, FRACS, FACS today has issued a stinging report regarding the unreliable PSA test, the mislabeling of the common Gleason 6 prostate disease as a cancer, and the misrepresentation that the radical (robotic) prostatectomy treatment is scientifically proven to be safe and effective – a charade that represents an outrageous and shameful trifecta of abominations. Read the article.

Active Surveillance for Intermediate Risk Prostate Cancer: Survival Outcomes in the Sunnybrook Experience.

Active Surveillance / By / / 1 minute of reading

Data from the survival outcomes of patients support the use of active surveillance in low risk and intermediate risk cases of Gleason 6 but not Gleason 7 prostate cancer. Multiparametric magnetic resonance imaging and novel biomarkers might be vital in detecting favorable Gleason 7 disease. Read the article here.

Scroll to Top